Bestard Matamoros, OriolCampistol Plana, Josep M.Morales, José M.Sánchez-Fructuoso, A.Cabello, MercedesCabello, VirginiaPallardó, Luis M.Grinyó Boira, Josep M.2016-01-112016-01-112012-01-010211-6995https://hdl.handle.net/2445/68648The development of new immunosuppressants for renal transplantation is aimed not only at improving short-term outcomes, but also at achieving better safety, cardiovascular, and metabolic profiles and at decreasing nephrotoxicity. Belatacept is a fusion protein that inhibits T cell activation by binding to CD80 and CD86 antigens. Clinical trials, particularly the BENEFIT and BENEFIT-EXT studies, have shown that belatacept preserves function and structure in renal grafts. The effects of belatacept provide long-term, sustained results, and the safety and efficacy of this drug have been demonstrated in cases of renal transplantation from expanded criteria donors. Compared to calcineurin inhibitors, belatacept is associated with a lower incidence of chronic allograft nephropathy and a more favourable cardiovascular and metabolic profile.11 p.application/pdfspacc-by-nc-nd (c) Sociedad Española de Nefrología, 2012http://creativecommons.org/licenses/by-nc-nd/3.0/esTrasplantament renalImmunosupressorsFactors de risc en les malaltiesCorKidney transplantationImmunosupressive agentsRisk factors in diseasesHeartinfo:eu-repo/semantics/article6216882016-01-11info:eu-repo/semantics/openAccess